Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Xing Li, Lijiang Gu, Yuhang Chen, Yue Chong, Xinyang Wang, Peng Guo, and Dalin He

ABSTRACT

Objective: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the survival outcomes of urinary system cancers; however no agreement has been reached. This meta-analysis aimed to explore the prognostic significance of pre-treatment SII in tumours of the urinary system.

Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to 30 August 2020. The hazard ratios (HRs) with 95% confidence intervals (CIs) were computed to estimate the associations of pre-treatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS) in urinary system cancers.

Results: 13 papers were included in our meta-analysis. From the combined data, we found that a high pre-treatment SII indicated a markedly worse OS (HR = 1.98; 95% CI: 1.75–2.23; p < .001), PFS (HR: 2.08; 95% CI: 1.32–3.26; p = .002), and CSS (HR: 2.41, 95% CI: 1.73–3.35, p < .001). Additionally, patients with an elevated SII value might have undesirable pathological characteristics, including a large tumour size, a poor differentiation grade, and an advanced tumour stage (all p < .001).

Conclusions: Pre-treatment SII could be used as a non-invasive and promising biomarker to indicate the prognosis of urinary system cancer patients.

KEY MESSAGES:

- This meta-analysis evaluates the predictive value of systemic immune-inflammation index (SII) for patients with urinary system cancer.
- A high pre-treatment SII indicates a poor prognosis.
- SII can serve as a promising non-invasive biomarker to help clinicians assess the prognosis and develop treatment strategies for urinary system cancer patients.

Introduction

Currently, the incidence and death rates of human urinary system cancers are increasing each year and have become a major health concern in both developed and developing countries [1,2]. Based on the most recent Cancer Statistics in the United States, an estimated 59,120 new cancer cases and 33,820 cancer-related deaths due to urinary system cancers will occur in 2020 alone [3]. Prostate cancer (PC) is already the leading cause of cancer among men in the United States and some other Western countries [4]. Additionally, the remaining common malignancies of the urinary system, such as kidney, bladder, and upper urinary tract cancers, also pose a serious threat...
to human health [5–7]. Although surgical techniques and medical therapies (e.g. chemotherapy, radiotherapy, and immunotherapy) have been rapidly developed in the last 10 years, the 5-year survival rate of patients with urinary system cancers remains dismal [8,9]. Therefore, useful new biomarkers to diagnose, evaluate and even the prognosis of urinary system cancers should be identified in clinical practice.

Recently, several parameters and molecules associated with the immune response extracted from blood samples have been proven to serve as new biomarkers for predicting the treatment effect or prognosis of patients with different cancers regardless of the therapeutic regimen [10–13]. The systemic immune-inflammation index (SII), a novel inflammatory marker, is associated with the clinicopathological features and prognosis of several cancers, such as colorectal cancer, breast cancer, hepatocellular carcinoma and PC [14–17]. The SII is calculated using the following formula: SII = platelet count × neutrophil count/lymphocyte count. Compared with other common inflammatory parameters, such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and C-reactive protein/albumin ratio, this parameter contains three types of peripheral blood inflammatory cells simultaneously, reflecting the balance of inflammation and the immune response of the body better while still being easy to measure at a low cost.

In recent years, the relationship of SII with urinary system malignancies has been explored and analysed in numerous studies [18–20]. However, because of the various experimental regions and subjects, the results of previous studies have been inconsistent. To our best knowledge, no systematic review or meta-analysis has been reported concerning the SII in urinary system tumours until now. Thus, this study aimed to comprehensively analyse the prognostic significance of the SII in patients with common urinary system cancers using previous relevant studies.

Materials and methods

Information sources and search strategy

A systematic literature search of relevant publications up to August 30, 2020, was performed by 2 authors independently using Web of Science, PubMed, Embase, and the Cochrane Library and the following terms: ("systemic immune-inflammation index" OR "SII") AND ("cancer" OR "tumour" OR "carcinoma" OR "neoplasm"). Additional studies were searched manually by scanning the reference lists of eligible original publications, review articles, and other relevant studies. The requirement for ethical approval and informed consent was waived because all the analyses in this study were based on previously published reports. Additionally, we prospectively registered the review methodology of this meta-analysis in PROSPERO (registration number: CRD42020203389).

Inclusion and exclusion criteria

Articles were included if they met the following criteria [1]: the articles investigated the relationship of the pre-treatment SII with the prognosis in any histologically confirmed urinary system cancer [2]; a specific cut-off value of the SII divided the patients into high and low groups [3]; the articles had sufficient data to evaluate the hazard ratio (HR) and 95% confidence interval (CI) of survival.

Furthermore, publications were disqualified if they met the following criteria [1]: they were duplicate articles, reviews, conference summaries and letters [2]; they were basic medical experiments, non-human studies, case reports and editorials [3]; the studies had unavailable data.

Data extraction

Two of our research investigators independently evaluated the study characteristics and extracted the survival data from the retrieved publications. Any disagreements were resolved by discussion and negotiation between them or eventually reviewed by a third individual. The following data were extracted from each qualified article: name of the first author, year of publication, region, study period, type of cancer, sample size, treatment strategy, cut-off value, survival outcomes, and median follow-up time. Additionally, if only Kaplan-Meier curves were presented in a study, the survival data were collected from the graphical survival plots utilising the software Engauge Digitiser 10.8 and the method of Tierney et al. [21] Additionally, if both multivariate and univariate analyses data were provided simultaneously, the HR and 95% CI data were extracted from the former analysis rather than from the latter.

Quality assessment

The quality of each study was carefully assessed by the two authors using the Newcastle-Ottawa Scale (NOS; Stang, 2010) on a score scale of 0–9 points. A high-quality study was identified as one with a score of 6 and greater.
**Statistical analysis**

All statistical analyses of the data were performed utilising Stata version 14.0 software (Stata Corporation, College Station, TX). Cochran’s Q-test and Higgin’s $I^2$ statistic were employed to measure the heterogeneity among the selected articles. The estimation of the HR and 95% CI was pooled using the fixed-effects model if the heterogeneity was not statistically significant ($p \geq .05$ or $I^2 \leq 50\%$). Otherwise, the random-effects model was used. Additionally, the presence of publication bias was evaluated visually by Begg’s funnel plot and Egger’s test. Furthermore, we performed sensitivity analysis to assess the reliability and stability of the results. Statistical significance was defined as $p < .05$.

**Results**

**Search results and study characteristics**

The selection procedure is presented in Figure 1. Initially, a total of 412 published articles were identified using the electronic database search. After removing duplicate records and screening the titles and/or abstracts, nineteen studies were reviewed by full text. Subsequently, 6 studies were excluded for the following reasons: 3 studies provide insufficient data for calculating survival outcomes, 1 study did not divide patients into high and low groups, and 2 studies had NOS scores of less than 6. Finally, 13 publications involving 3974 patients were enrolled in the current meta-analysis. Notably, among these 13 studies, two

![Figure 1. Flow diagram of the study selection process.](image-url)
contained training and validation cohorts simultaneously; thus, we eventually conducted a comprehensive analysis and statistical processing of 15 datasets.

The included studies were published from 2016 to 2020, with a sample size between 70 and 646 and a cut-off value of the SII between 200 and 1375. Of them, six studies assessed the relationship between SII and prognosis in renal cell carcinoma (RCC) patients [19,22–26], two investigated upper tract urothelial carcinoma (UTUC) [20,27], two focussed on bladder cancer (BC) [28,29], and three explored PC [18,30,31]. In terms of the research quality evaluation, the NOS score was 9 for three datasets, 8 for six datasets, 7 for one dataset, and 6 for five datasets, demonstrating that the included articles were of high quality. Other more detailed features of the enrolled studies are listed in Table 1.

**Table 1. Basic characteristics of the included studies.**

| Study   | Year | Region  | Study period | Cancer type | Sample size | Treatment strategy | Cut-off value | Cut-off selection | Study type | Survival analysis | Follow-up time | NOS |
|---------|------|---------|--------------|-------------|-------------|-------------------|--------------|------------------|------------|------------------|---------------|-----|
| Teishima| 2020 | Japan   | 2008–2018    | RCC         | 179         | NS                | 730          | Previous studies | MC/CC     | OS               | <5 years       | 8   |
| Ozbek   | 2020 | Turkey  | N            | RCC         | 176         | WS                | 800          | ROC analysis     | SC/CC     | OS, CSS          | >5 years       | 9   |
| Hu      | 2020 | China   | 2010–2013    | RCC         | 646         | WS                | 529          | ROC analysis     | SC/CC     | OS, CSS          | >5 years       | 8   |
| De Giorgi| 2019 | Italy   | 2015–2016    | RCC         | 313         | NS                | 1375         | X-tile software | MC/CC     | OS               | <5 years       | 6   |
| Chrom   | 2019 | Poland  | 2008–2016    | RCC         | 502         | NS                | 730          | Previous studies | DC/CC     | OS               | >5 years       | 7   |
| Lolli   | 2016 | Italy   | N            | RCC         | 335         | NS                | 730          | X-tile software | MC/CC     | PFS              | <5 years       | 6   |
| Zheng   | 2020 | China   | 2006–2015    | UTUC        | 253 (TC)    | WS                | 672.44       | ROC analysis     | DC/CC     | OS, CSS, PFS     | <5 years       | 8   |
| Jan     | 2018 | Taiwan  | 2007–2017    | UTUC        | 424         | WS                | 672.44       | ROC analysis     | DC/CC     | OS, CSS, PFS     | <5 years       | 8   |
| Yilmaz  | 2020 | Turkey  | 1999–2019    | BC          | 152         | WS                | 768          | ROC analysis     | SC/CC     | OS, PFS          | <5 years       | 6   |
| Zhang   | 2019 | China   | 2005–2019    | BC          | 139 (TC)    | WS                | 507          | X-tile software | SC/CC     | OS               | >5 years       | 9   |
| Man     | 2019 | China   | 2010–2018    | PC          | 179         | NS                | 535          | Previous studies | SC/CC     | OS               | <5 years       | 8   |
| Fan     | 2017 | China   | 2013–2017    | PC          | 104         | NS                | 200          | ROC analysis     | SC/CC     | OS, PFS          | <5 years       | 6   |
| Lolli   | 2016 | Italy   | 2011–2015    | PC          | 230         | NS                | 535          | X-tile software | MC/CC     | OS               | <5 years       | 6   |

RCC: renal cell carcinoma; UTUC: upper tract urothelial carcinoma; BC: bladder cancer; PC: prostate cancer; TC: training cohort; VC: validation cohort; MC: multi-centre; SC: single centre; DC: double centre; CC: case control; CS: cohort study; NS: no surgery; WS: with surgery; ROC: receiver operating characteristic; OS: overall survival; PFS: cancer-specific survival; CSS: progression-free survival; NOS: Newcastle-Ottawa quality assessment scale.

**Prognostic significance of the SII for OS in urinary system cancers**

All the studies reported the association between the pre-treatment SII and overall survival (OS) in urinary system cancer patients. As shown in Figure 2(A), the combined HR was 1.98 with the corresponding 95% CI (1.75–2.23), demonstrating that patients with a high SII would have a worse OS than those with a low SII ($p < .001$). Because there was no remarkable heterogeneity, the fixed-effects model was used ($I^2 = 17.0%$; $p = .904$). Additionally, subgroup analysis of OS based on the sample size, tumour location, urothelial carcinoma (yes or no), treatment strategy, cut-off value, and follow-up years further supported the above results and revealed that the sample size, tumour location, urothelial carcinoma (yes or no) and treatment strategy might be potential causes of the slight heterogeneity (Table 2).

**Prognostic significance of the SII for PFS in urinary system cancers**

Six datasets involving 1540 patients focussing on the correlation of the pre-treatment SII with progression-free survival (PFS). The combined result showed that a high SII indicated a poor PFS in patients (HR: 2.08; 95% CI: 1.32–3.26; $p = .002$) (Figure 2(B)). A random-effects model was used because of heterogeneity ($I^2 = 80.8%$; $p < .001$). Therefore, we performed subgroup analysis to evaluate whether the heterogeneity was related to the same variables as above. The results demonstrated that a sample size less than 200, lower urinary tract tumour, non-urothelial carcinoma, non-surgical treatment, a cut-off value less than 600, and a median follow-up not longer than 5 years might be the major sources of heterogeneity; however, these results did not reverse the conclusion (Table 3).

**Prognostic significance of the SII for CSS in urinary system cancers**

Only four studies involving five datasets investigated the relationship between the pre-treatment SII and cancer-specific survival (CSS). The pooled data suggested that, compared with a low SII, a high SII was related to a worse CSS (HR: 2.41; 95% CI: 1.73–3.25; $p < .001$; Figure 2(C)). Fortunately, no significant heterogeneity was observed among these studies. Thus, a random-effects model was used to analyse the prognostic value of the SII for CSS in urinary system cancer patients ($I^2 = 0$; $p = 904$).
Correlations between the SII and clinicopathological factors in urinary system cancers

Overall, 9 datasets comprising 2338 patients reported the associations of the SII with clinicopathological characteristics, and the major features in our study included age (old versus young) in nine datasets, sex (male versus female) in eight datasets, tumour size (large versus small) in five datasets, differentiation grade (poor versus well) in five datasets, and tumour stage (III/IV versus I/II) in six datasets. The fixed-effects model or random-effects model was used based on the presence or absence of heterogeneity. No obvious correlation was observed between the pre-treatment SII and age of urinary system cancer patients regardless of whether the binary variables or continuous variables were used for calculation (OR = 1.12, 95% CI: 0.90–1.39, p = .315; SMD = −0.05, 95% CI: −0.43–0.34, p = .817; Table 4 and Figure 3). However, the pooled results revealed that a pre-treatment high SII was significantly related to a large tumour size (OR = 1.89; 95% CI: 1.49–2.40; p < .001), a poor differentiation grade (OR = 1.66; 95% CI: 1.31–2.12; p < .001), and an advanced tumour stage (OR = 2.36; 95% CI: 1.67–3.34; p < .001). Additionally, male patients generally had a high pre-treatment SII value compared with female patients (OR = 1.37; 95% CI: 1.13–1.67; p = .002).

Publication bias

Both Egger’s tests and Begg’s funnel plot were performed to evaluate the potential publication bias of the included studies. Regarding the meta-analysis of the relationship of the pre-treatment SII with OS, no obvious publication bias was detected by Egger’s test (p = .060); however, Begg’s funnel plot appeared to be asymmetric (p = .029) (Figure 4(A)). Thus, we used the “trim and fill” method to explore the potential “missing” studies. Finally, 5 hypothetically missing studies were identified, and the recombined HR was 1.80 with the corresponding 95% CI (1.61–2.01), which did not differ from the initial results (Figure 4(B)). Additionally, no remarkable bias was observed in the analysis of the associations of pre-treatment SII with PFS (Egger’s test: p = .396; Begg’s test: p = .133) (Figure 4(C)) and CSS (Egger’s test: p = .729; Begg’s test: p = .806) (Figure 4(D)).

Sensitivity analysis

Sensitivity analysis was conducted to evaluate the reliability of the combined HRs of OS, PFS and CSS by omitting each study from the analysis sequentially (Figure 5). No single study affected the conclusions, supporting that the pooled results were relatively steady and reliable.
Table 2. Subgroup analysis of the pooled HR and 95% CI between SII and OS in urinary system cancers.

| Variables Included datasets | Patients (n) | HR (95% CI) | p-Value | I² (%) | p-Value | Model |
|-----------------------------|--------------|-------------|---------|--------|---------|-------|
| Total                       | 15           | 3974        | 1.98 (1.75–2.23) | <.001 | 17.0 | .263 |
| Sample size                 |              |             |         |        |        |       |
| <200                        | 7            | 999         | 2.09 (1.60–2.75) | <.001 | 35.0 | .161 |
| ≥200                        | 8            | 2975        | 1.95 (1.70–2.23) | <.001 | 5.8 | .386 |
| Tumour location             |              |             |         |        |        |       |
| Upper tract                 | 9            | 3100        | 1.96 (1.71–2.24) | <.001 | 0.5 | .429 |
| Lower tract                 | 6            | 874         | 2.03 (1.57–2.26) | <.001 | 43.0 | .118 |
| Urothelial carcinoma        |              |             |         |        |        |       |
| N                           | 9            | 2664        | 1.99 (1.74–2.27) | <.001 | 30.8 | .172 |
| Y                           |              |             |         |        |        |       |
| Treatment                   |              |             |         |        |        |       |
| NS                          | 7            | 1842        | 1.95 (1.70–2.25) | <.001 | 44.0 | .098 |
| WS                          | 8            | 2132        | 2.05 (1.62–2.59) | <.001 | 0.5 | .34 |
| Cut-off value               |              |             |         |        |        |       |
| <600                        | 7            | 1792        | 2.25 (1.80–2.81) | <.001 | 0.0 | .447 |
| ≥600                        | 8            | 2182        | 1.88 (1.63–2.17) | <.001 | 24.9 | .230 |
| Follow-up years             |              |             |         |        |        |       |
| <5                          | 10           | 2441        | 2.01 (1.73–2.34) | <.001 | 21.0 | .250 |
| ≥5                          | 5            | 1533        | 1.92 (1.57–2.34) | <.001 | 25.0 | .255 |

SII: systemic immune-inflammation index; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; N: no; Y: yes; NS: no surgery; WS: with surgery.

Table 3. Subgroup analysis of the pooled HR and 95% CI between SII and PFS in urinary system cancers.

| Variables Included datasets | Patients (n) | HR (95% CI) | p-Value | I² (%) | p-Value | Model |
|-----------------------------|--------------|-------------|---------|--------|---------|-------|
| Total                       | 6            | 1540        | 2.08 (1.32–3.26) | .002 | 80.8 | <.001 |
| Sample size                 |              |             |         |        |        |       |
| <200                        | 2            | 256         | 4.21 (0.58–30.80) | .156 | 94.5 | <.001 |
| ≥200                        | 4            | 1284        | 1.64 (1.35–1.99) | <.001 | 0 | .958 |
| Tumour location             |              |             |         |        |        |       |
| Upper tract                 | 4            | 1284        | 1.64 (1.35–1.99) | <.001 | 0 | .958 |
| Lower tract                 | 2            | 256         | 4.21 (0.58–30.80) | .156 | 94.5 | <.001 |
| Urothelial carcinoma        |              |             |         |        |        |       |
| N                           | 2            | 439         | 4.35 (0.66–28.82) | .128 | 95.7 | <.001 |
| Y                           |              |             |         |        |        |       |
| Treatment                   |              |             |         |        |        |       |
| NS                          | 2            | 439         | 4.35 (0.66–28.82) | .128 | 95.7 | <.001 |
| WS                          | 4            | 1101        | 1.54 (1.18–2.01) | .001 | 0 | .998 |
| Cut-off value               |              |             |         |        |        |       |
| <600                        | 2            | 528         | 4.21 (0.58–30.56) | .155 | 94.9 | <.001 |
| ≥600                        | 4            | 1012        | 1.64 (1.34–1.99) | 0 | 0 | .958 |
| Follow-up years             |              |             |         |        |        |       |
| <5                          | 6            | 1540        | 2.08 (1.32–3.26) | .002 | 80.8 | <.001 |
| ≥5                          | 0            | 0           | 0       | 0 | 0 | 0 |

SII: systemic immune-inflammation index; PFS: progression-free survival; HR: hazard ratio; 95% CI: 95% confidence interval; N: no; Y: yes; NS: no surgery; WS: with surgery.

Table 4. Correlation between SII and clinicopathological features in urinary system cancers.

| Variables                  | Included studies | Patients (n) | OR (95% CI) | p-Value | I² (%) | p-Value | Model |
|---------------------------|------------------|--------------|-------------|---------|--------|---------|-------|
| Age (old vs. young)       | 6                | 1337         | 1.12 (0.90–1.39) | .315 | 0 | .554 |
| Binary variables          |                  |              |             |         |        |        | Fixed-effects |
| Continuous variables      | 3                | 1001         | −0.05 (−0.43–0.34) | .817 | 84.3 | .002 |
| Gender (male vs. female)  | 8                | 2159         | 1.37 (1.13–1.67) | .002 | 0 | .430 |
| Tumour size (large vs. small) | 5              | 1158         | 1.89 (1.49–2.40) | <.001 | 35.6 | .184 |
| Differentiation grade (poor vs. well) | 5          | 1774         | 1.66 (1.31–2.12) | <.001 | 45.9 | .116 |
| Tumour stage (III/IV vs. I/II) | 6            | 1804         | 2.36 (1.67–3.34) | <.001 | 55.7 | .046 |

OR: odds ratio; SMD: standard mean difference; 95% CI: 95% confidence interval; vs: versus; *SMD.
Although several studies have previously reported the association of SII with urinary system cancers, we found some inconsistencies among the various results. In the present meta-analysis, we systematically evaluated the potential value of SII for predicting the clinicopathological features and prognosis of urinary system cancer patients who had undergone non-surgical or surgical treatment. Our statistical analyses showed that elevated levels of the pre-treatment SII are more likely to be associated with poor survival outcomes, such as shorter OS, PFS, and CSS, and undesirable pathological features, such as a large tumour size, a poor differentiation grade, and an advanced tumour stage. To our best knowledge, this meta-analysis is the first to investigate whether SII can...
be used as an independent prognostic marker for patients with urinary system cancer regardless of the treatment strategy.

As early as 1863, Virchow found abnormal leucocyte cells in cancerous tissues and formulated a hypothesis that a correlation existed between the inflammatory response and cancer progression [32]. Later, an increasing number of studies began to explore the potential mechanisms by which inflammation affects tumours using animal models and clinical trials [33,34]. The SII, as a new inflammatory index that is simple, economic, and easily detected, has been proposed and has received more attention in recent years; it is calculated based on the counts of peripheral neutrophils, platelets, and lymphocytes. The SII is related to the occurrence, progression, and prognosis of several diseases, such as bleeding disorders, connective tissue diseases, and various malignant tumours in humans [35–37].

In 2014, using retrospective and prospective studies, Hu and his colleagues first demonstrated that the SII was a strong prognostic indicator of adverse outcomes for hepatocellular carcinoma (HCC) patients and could be a promising tool to aid in the decision making of therapeutic strategies for HCC [38]. Although the precise mechanism by which the SII affects cancer prognosis has not been fully clarified presently, it is at least related to the three inflammatory biomarkers involved in the SII calculation. First, neutrophils can secrete various inflammatory factors, such as vascular endothelial growth factor, interleukin (IL)-6, IL-10, and prostaglandin, to accelerate the construction of the tumour microenvironment, which plays a critical role in promoting tumour angiogenesis, enhancing tumour cell adhesion and facilitating distant metastasis [11,12]. Second, platelets, as the shield of circulating tumour cells, may prevent them from endogenous and exogenous immune attacks, leading to the multiplication, invasion and metastasis of the tumour [39]. At the same time, platelets can also release several chemokines and cytokines and exert effects similar to those of neutrophils in vivo [40]. Thus, the enhanced neutrophil and platelet counts reflect the opening of the immune pathways and activation of the immune state in the organism. By contrast, lymphocytes, particularly tumour-infiltrating

Figure 4. Detection of publication bias for meta-analysis of survival outcomes (A, OS: Begg’s funnel plot; B, OS: Filled funnel plot with “trim-and-fill” method; C, PFS; D, CSS).
lymphocytes, may induce the apoptosis of tumour cells and eliminate them through specific cellular immunity and humoral immunity, which is essential for immune defence and immune surveillance in the host [41,42]. Based on the above mechanisms, it is easily understandable that a high SII indirectly symbolises the inadequate immunological function of cancer patients and intensification of tumour invasiveness. Therefore, this compound immunity index is more likely to predict the undesirable pathological features and worse survival of cancer patients.

Previously, several studies have explored the prognostic impact of the SII in tumours of different organs and systems using systematic reviews and meta-analyses. In 2017, Zhong et al. first demonstrated that a high SII predicted the poor outcomes of patients with solid tumours and could be considered a new cost-effective prognostic indicator [43]. Zhang and his colleagues provided evidence in 2018 that the SII, as an easily obtained and non-invasive biomarker, was associated with a short OS (HR: 1.52; 95% CI: 1.29–1.74; \( p < .01 \)), DFS (HR: 2.28; 95% CI: 1.46–3.10; \( p < .01 \)) and recurrence-free survival (RFS) (HR: 1.60; 95% CI: 1.19–2.00; \( p < .01 \)) in patients with gastrointestinal (GI) cancers and could become a powerful tool in predicting the survival of GI cancers in clinical practice [44]. Recently, the prognostic value of the pre-treatment SII in non-small cell lung cancer patients was also proven by Wang et al. They supported that this immune parameter was helpful for physicians to develop therapeutic strategies, and patients with a high SII should be recommended for immunotherapy compared with those with a low SII [45]. In recent years, many studies have successively explored the correlation between the SII and urinary malignant tumours. An Italian scientific research team performed a retrospective study involving 335 patients with terminal RCC receiving sunitinib and suggested that SII and its changes during immunological therapy could effectively predict the prognosis of patients with metastatic RCC [26]. In Zheng’s study of patients with UTUC undergoing radical nephroureterectomy, the patients with a high SII before surgery had a markedly shorter OS, PFS, and CSS than those with a low SII (all \( p < .05 \)) [20]. The findings of Man et al. and Fan et al. directly proved that the pre-treatment SII could assist in predicting the survival of metastatic castration-resistant PC patients treated with chemotherapy in both the training and validation cohorts. Thus, the pre-treatment SII, combined with other indices (prostate-specific antigen, albumin, and fibrinogen), might guide clinicians in the identification of high-risk populations and selection of the best treatment protocols [18,30]. In 2020, Yılmaz et al. found that the SII and other parameters, such as the NLR, prognostic nutritional index, and red cell distribution, were associated with poor survival outcomes in patients with muscle-invasive bladder cancer (MIBC) in univariate analysis. Unfortunately, the SII was not found to be an independent prognostic indicator for either OS (HR: 1.551; 95% CI: 0.877–2.774; \( p = .131 \)) or

**Figure 5.** Sensitivity analysis of the relationship between SII and survival outcomes (A, OS; B, PFS; C, CSS).
PFS (HR: 1.240; 95% CI: 0.670–2.294; \( p = .493 \)) in multivariate analysis [28]. However, in a similar study of MIBC, Zhang et al. revealed that an elevated preoperative SII could be considered an independent predictor for patients undergoing radical cystectomy in both univariate and multivariate Cox regression analyses, and the SII was more predictive than the NLR and PLR [29]. The heterogeneity may be caused by the differences in the study regions, inconsistency of the SII cut-off values, and various tumour types. The results of our meta-analysis further confirmed the critical prognostic value of the SII for urinary system cancers. Therefore, we recommend that SII should be applied to the prognostic risk assessment system for urinary system cancer patients.

However, the present meta-analysis has several limitations. First, most of the articles included in our meta-analysis were retrospective studies, which inevitably led to potential defects and deviations in the original data. Second, only 13 studies involving 15 datasets comprising 3974 patients were enrolled, likely causing bias due to the limited sample size. Third, because of the differences in cut-off selection, the critical values of the SII have not yet been unified. Fourth, the treatment strategies are not exactly the same in various cancer types; these inconsistencies may influence the survival of patients, producing heterogeneity. Finally, potential publication bias cannot be avoided entirely. Therefore, the prognostic role of the pre-treatment SII in urinary system cancers needs to be further explored by conducting more large-scale and high-quality prospective trials in the future.

**Conclusion**

In this relatively detailed comprehensive study, our findings provide evidence that an elevated pre-treatment SII is markedly correlated with unfavourable survival outcomes and adverse pathological characteristics in patients with urinary system cancers. Hence, the SII can serve as an effective prognostic indicator to help clinicians assess the prognosis and develop treatment strategies for these patients.

**Acknowledgements**

We gratefully acknowledge the time and energy contributed by all the researchers.

**Ethical approval**

Because all the analyses were based on previously published studies, ethical approval and informed consent were not required.

**Author contributions**

Conceptualisation: XL, DLH; Data curation: XL, LJG, YHC, YC; Formal analysis: XL, LJG; Investigation: XL, LJG, YHC, YC, XYW, PG, DLH; Methodology: XL, LJG, YHC, YC, XYW, PG, DLH; Resources: DLH; Software: XL, LJG, YHC, YC; Supervision: DLH, PG; Writing – original draft: XL, LJG, YHC, YC, XYW, PG, DLH; Writing – review & editing: XL, LJG, YHC, YC, XYW, PG, DLH. All the authors have read and approved the manuscript.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This study was supported by grants from the National Natural Science Foundation of China [NSFC No. 81672958 to DLH].

**Data availability statement**

The data that support the findings of this study are available on request from the corresponding author.

**References**

[1] Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.

[2] Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–874.

[3] Siegel RL, Miller KD, Jemal A. Jemal A: cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.

[4] Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.

[5] Palumbo C, Pecoraro A, Knipper S, et al. Contemporary age-adjusted incidence and mortality rates of renal cell carcinoma: analysis according to gender, race, stage, grade, and histology. Eur Urol. 2021;7(3):644–652.

[6] Cai Q, Chen Y, Xin S, et al. Temporal trends of bladder cancer incidence and mortality from 1990 to 2016 and projections to 2030. Transl Androl Urol. 2020;9(2):153–165.

[7] Zamboni S, , Foerster B, Abufaraj M, et al. Incidence and survival outcomes in patients with upper urinary
[8] Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018;4(11):1535–1542.

[9] Kaur I, Doja MN, Ahmad T. Time-range based sequential mining for survival prediction in prostate cancer. J Biomed Inform. 2020;110:103550.

[10] Zengin M, Karahan I. The role of cancer-related inflammation for prediction of poor survival in post-menopausal female patients with stage II/III Colon cancer. Int Immunopharmacol. 2020;85:106624.

[11] Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist. 2017;22(6):737–742.

[12] Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23(1):31–39.

[13] Szewczyk G, Maciejewski T, Szukiewicz D. Current progress in the inflammatory background of angiogenesis in gynecological cancers. Inflamm Res. 2019;68(4):247–260.

[14] Dong M, Shi Y, Yang J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920937425.

[15] Chen L, Kong X, Wang Z, et al. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020;24(5):2993–3021.

[16] Zhao LY, Yang DD, Ma XK, et al. The prognostic value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments. J Cancer. 2019;10(10):2299–2311.

[17] Murray NP, Fuentelba C, Salazar A, et al. Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy. Turk J Urol. 2020;46(2):115–122.

[18] Man YN, Chen YF. Systemic immune-inflammatory index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Int Urol Nephrol. 2019;51(12):2189–2199.

[19] Teishima J, Inoue S, Hayashi T, et al. Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. CUAJ. 2020;14(11):E582–E587.

[20] Zheng Y, Yu D, Yu Z, et al. Association of preoperative systemic immune-inflammation index and prognostic nutritional index with survival in patients with upper tract urothelial carcinoma. J Cancer. 2020;11(19):5665–5677.

[21] Tierney JF, Stewart LA, Gheri D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: Artn 16 10.1186/1745-6215-8:16.

[22] Ozek E, Besiroglu H, Ozer K, et al. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol. 2020;52(8):1455–1463.

[23] Hu X, Shao YX, Yang ZQ, et al. Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis. Cancer Cell Int. 2020;20:222.

[24] De Giorgi U, Procopio G, Giannarelli D, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019;25(13):3839–3846.

[25] Chrom P, Zolnierek J, Bodnar L, et al. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. Int J Clin Oncol. 2019;24(5):526–532.

[26] Lolli C, Basso U, Derosa L, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7(34):54564–54571.

[27] Jan HC, Yang WH, Ou CH. Combination of the preoperative systemic immune-inflammation index and monocyte-lymphocyte ratio as a novel prognostic factor in patients with upper-tract urothelial carcinoma. Ann Surg Oncol. 2019;26(2):669–684.

[28] Yilmaz A, Yilmaz H, Tekin SB, et al. The prognostic significance of hemoglobin-to-red cell distribution width ratio in muscle-invasive bladder cancer. Biomark Med. 2020;14(9):727–738.

[29] Zhang W, Wang R, Ma W, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.

[30] Fan L, Wang R, Chi C, et al. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate. 2018;78(4):250–256.

[31] Lolli C, Caffo O, Scarpi E, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol. 2016;7:376.

[32] Balk will F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.

[33] Elinav E, Nowarski R, Thais CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771.

[34] Ahn KS, Hwang JY, Han HS, et al. The impact of acute inflammation on progression and metastasis in...
Li S, Liu K, Gao Y, et al. Prognostic value of systemic immune-inflammation index in acute/subacute patients with cerebral venous sinus thrombosis. Stroke Vasc Neurol. 2020;5(4):368–373.

Tanacan E, Dincer D, Erdogan FG, et al. A cutoff value for the systemic immune-inflammation index in determining activity of Behcet disease. Clin Exp Dermatol. 2021;46(2):286–291.

Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort Study. Ann Surg. 2019;270(1):139–146.

Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222.

Li N. Platelets in cancer metastasis: to help the “villain” to do evil. Int J Cancer. 2016;138(9):2078–2087.

Gao L, Zhang H, Zhang B, et al. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer. Oncotarget. 2017;8(9):15632–15641.

Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444.

Gooden MJM, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.

Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–75388.

Zhang Y, Lin S, Yang X, et al. Prognostic value of pre-treatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol. 2019;234(5):5555–5563.

Wang Y, Li Y, Chen P, et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. Ann Transl Med. 2019;7(18):433–433.